CC-90005

oral, selective PKC_ kinase inhibitor

Ph. I candidate for Psoriasis

from screen of internal library and SBDD

Journal of Medicinal Chemistry

Celgene/BMS, San Diego, CA, USA

The Celgene/BMS PKCθ kinase inhibitor, CC-90005, highlighted by Julien Lefranc, is a clinical candidate in Ph. I for psoriasis, with some dosing being conducted in healthy volunteers. The safety profile is…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.